A multicenter, real life study evaluating efficacy and safety of Daclatasvir+Sofosbuvir, with or without Ribavirin in Hepatitic C virus genotype 1,2,3,4 patients.
Latest Information Update: 25 May 2017
At a glance
- Drugs Daclatasvir (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 25 May 2017 New trial record
- 09 May 2017 Results presented at the Digestive Disease Week 2017